PBT fell 37.1% on 11.3% revenue growth as working capital absorbed NZ$25.9m

This absorption, driven by a NZ$8.4m rise in contract assets and a NZ$13.7m fall in contract liabilities, flipped operating cash flow from a NZ$26.0m inflow in HY23 to a NZ$7.7m outflow, and pushed pre-lease free cash flow to NZ$-12.8m — below the company's historical range of NZ$-10.0m to NZ$24.5m.

Against that cash backdrop, operating EBITDA rose 13.9% to NZ$16.6m on revenue growth of 11.3% to NZ$140.9m, and the EBITDA margin reached 11.8%, an unprecedented high versus the four-period mean of 10.5%. However, one-off strategic review costs and higher depreciation and interest charges dragged PBT down 37.1% to NZ$6.1m — an unprecedented low against a historical mean of 13.1% growth.

NPAT fell 44.3% to NZ$4.4m, the decline amplified by the effective tax rate rising to 26.4% from 19.3% in HY23.

The NZ$25.9m absorption sits NZ$19.0m above the historical mean and is driven by the project mix shifting toward Materials Handling & Logistics (MHL), whose revenue share rose to 44.5% from 36.8% as Protein declined from 27.2% to 22.2%. MHL's gross margin is already the weakest at 19%, and project-timing milestones in contract recognition typically precede cash receipt — meaning this working-capital position may not reverse quickly if delivery schedules slip.

The gap between EBITDA and PBT reveals a structural cost increase. Management attributed the PBT collapse to one-off strategic review costs alongside higher depreciation and interest. Gross borrowings nearly doubled to NZ$34.2m from NZ$17.2m, pushing net debt to NZ$20.7m from a net cash position of NZ$12.8m in HY23, and net debt/EBITDA to 1.2x — above the company's historical range of up to 1.1x. This leverage shift, combined with the higher capex (NZ$5.1m versus NZ$1.6m), represents a permanent cost change that EBITDA improvement alone does not offset.

The interim dividend payout ratio reached an unprecedented 90.9% of NPAT, against a historical mean of 60.0% and a prior HY23 ratio of 40.8%. With free cash flow negative this half, the interim dividend is not being covered by operating cash generation, which adds balance-sheet pressure at a time when borrowings have already risen substantially.

That shape, combined with management's commentary about carrying NZ$195m in forward work into FY24 (as noted at the FY23 result), supports the view that H2 FY24 revenue and EBITDA can at least match the first half. However, there are no stated FY24 targets against which to judge this result directly.

The key uncertainty is whether the contract-asset build resolves into cash receipts in H2. If customer sign-offs occur as planned, much of the working-capital absorption should reverse. If they do not, leverage will continue to rise through the second half, limiting financial flexibility.

The Minerals segment delivered 34% gross margin on growing revenue, and the Rest of Business improved sharply from a 9% to a 30% margin, which is encouraging even if partially timing-driven.

Below EBITDA, however, the quality is weaker. The PBT result is depressed by one-off costs that management has not fully quantified in the available excerpts, higher depreciation from a growing asset base, and an interest charge reflecting nearly doubled borrowings. None of these unwind automatically. Cash generation is more concerning: operating cash flow was negative, and the pre-lease FCF of NZ$-12.8m sits below the company's historical range. This is not a clean working-capital timing story — the NZ$25.9m build is unprecedented and the project mix shift to lower-margin, longer-cycle MHL work means the timing of reversal is genuinely uncertain.

This briefing cannot assess whether the contract-asset build will reverse in H2 or extend further, as that depends on project delivery milestones and customer acceptance timing not disclosed in the available financial statements.